Ravi Srinivasan, i2o Therapeutics CEO
October 13, 2022 10:33 AM EDT
Financing

J&J and Sanofi-part­nered oral de­liv­ery biotech rais­es $26M on lat­est of­fer­ing

Lei Lei Wu

News Reporter

Ac­cord­ing to an SEC fil­ing Tues­day, i2o Ther­a­peu­tics raised $26 mil­lion in a pri­vate stock of­fer­ing.

The Har­vard spin­out start­ed out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times